Yang, Chin-YiChin-YiYangLai, Po-JuPo-JuLaiChen, Chun-BingChun-BingChenChan, Tom CTom CChanHui, Rosaline Chung-YeeRosaline Chung-YeeHuiHuang, Yu-HueiYu-HueiHuangTseng, Han-ChiHan-ChiTsengLin, Shang-HungShang-HungLinLu, Chun-WeiChun-WeiLuLee, Hua-EnHua-EnLeeLin, Jing-YiJing-YiLinChi, Min-HuiMin-HuiChiTsai, Ming-FengMing-FengTsaiHwang, Yih-ShiouYih-ShiouHwangWang, Chuang-WeiChuang-WeiWangCHIA-YU CHUChung, Wen-HungWen-HungChung2023-06-282023-06-282022-10-212077-0383https://scholars.lib.ntu.edu.tw/handle/123456789/633231To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18-87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator's Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month 12, while prurigo and lichenoid phenotypes were associated with a lower proportion of EASI-75 at month 12. However, the majority of adverse events were mild in severity. In conclusion, our study results identify phenotype-related dupilumab response at month 12 in adults with moderate-to-severe AD, and we suggest that treatment should not be discontinued until reaching a satisfactory clinical response.enatopic dermatitisbiomarkerdupilumabeczema phenotypeefficacy[SDGs]SDG3journal article10.3390/jcm11206209362945302-s2.0-85140799724